MacGregor A B, Falk R E, Landi S, Ambus U, Langer B
Surg Gynecol Obstet. 1975 Nov;141(5):747-54.
Forty-seven patients representing all stages of malignant melanoma have been treated orally with bacille Calmette Guérin as an adjunct to standard treatment regimens. This is a preliminary study, but it appears that orally administered bacille Calmette Guérin in localized disease may delay the development of local recurrence and distant spread. In patients with disseminated melanoma but without intracranial metastases, the survival time is increased from 4.0 to 12.7 months. It has no effect on the progress of disease in patients with intracranial metastases or in those with hepatic metastases from intraocular melanoma.
47例代表恶性黑色素瘤各阶段的患者接受了口服卡介苗治疗，作为标准治疗方案的辅助治疗。这是一项初步研究，但似乎局部疾病口服卡介苗可能会延迟局部复发和远处转移的发生。在播散性黑色素瘤但无颅内转移的患者中，生存时间从4.0个月增加到12.7个月。它对颅内转移患者或眼内黑色素瘤肝转移患者的疾病进展没有影响。
